These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 38521213

  • 21. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J, Chen C, Wang D, Zhang J, Zhang T.
    Eur J Med Chem; 2021 May 05; 217():113329. PubMed ID: 33740548
    [Abstract] [Full Text] [Related]

  • 22. Impaired B Cell Apoptosis Results in Autoimmunity That Is Alleviated by Ablation of Btk.
    Wright JA, Bazile C, Clark ES, Carlesso G, Boucher J, Kleiman E, Mahmoud T, Cheng LI, López-Rodríguez DM, Satterthwaite AB, Altman NH, Greidinger EL, Khan WN.
    Front Immunol; 2021 May 05; 12():705307. PubMed ID: 34512628
    [Abstract] [Full Text] [Related]

  • 23. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z, Zhang D, Liu Y, Yang D, Ran F, Wang ML, Zhao G.
    Arch Pharm (Weinheim); 2018 Jul 05; 351(7):e1700369. PubMed ID: 29741794
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
    Torke S, Pretzsch R, Häusler D, Haselmayer P, Grenningloh R, Boschert U, Brück W, Weber MS.
    Acta Neuropathol; 2020 Oct 05; 140(4):535-548. PubMed ID: 32761407
    [Abstract] [Full Text] [Related]

  • 25. Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.
    Nadeem A, Ahmad SF, Al-Harbi NO, Ibrahim KE, Alqahtani F, Alanazi WA, Mahmood HM, Alsanea S, Attia SM.
    Int Immunopharmacol; 2021 Jan 05; 90():107123. PubMed ID: 33168411
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis.
    Paliwal S, Bawa S, Shalmali N, Tonk RK.
    Chem Biol Drug Des; 2024 Jul 05; 104(1):e14582. PubMed ID: 39013795
    [Abstract] [Full Text] [Related]

  • 30. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
    Carnero Contentti E, Correale J.
    Drug Des Devel Ther; 2022 Jul 05; 16():3473-3490. PubMed ID: 36238195
    [Abstract] [Full Text] [Related]

  • 31. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.
    Garg N, Padron EJ, Rammohan KW, Goodman CF.
    J Clin Med; 2022 Oct 18; 11(20):. PubMed ID: 36294458
    [Abstract] [Full Text] [Related]

  • 32. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
    Nadeem A, Ahmad SF, Al-Harbi NO, El-Sherbeeny AM, Alasmari AF, Alanazi WA, Alasmari F, Ibrahim KE, Al-Harbi MM, Bakheet SA, Attia SM.
    Int Immunopharmacol; 2020 Mar 18; 80():106215. PubMed ID: 31982823
    [Abstract] [Full Text] [Related]

  • 33. A Fast and Clean BTK Inhibitor.
    Gabizon R, London N.
    J Med Chem; 2020 May 28; 63(10):5100-5101. PubMed ID: 32401033
    [Abstract] [Full Text] [Related]

  • 34. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.
    Clin Immunol; 2018 Dec 28; 197():205-218. PubMed ID: 30339790
    [Abstract] [Full Text] [Related]

  • 35. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases.
    Zhang D, Gong H, Meng F.
    Molecules; 2021 Aug 13; 26(16):. PubMed ID: 34443496
    [Abstract] [Full Text] [Related]

  • 36. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J.
    Curr Pharm Des; 2022 Aug 13; 28(6):437-444. PubMed ID: 34218776
    [Abstract] [Full Text] [Related]

  • 37. Bruton's Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia.
    de Porto AP, Liu Z, de Beer R, Florquin S, Roelofs JJTH, de Boer OJ, den Haan JMM, Hendriks RW, van 't Veer C, van der Poll T, de Vos AF.
    Front Immunol; 2021 Aug 13; 12():723967. PubMed ID: 34552589
    [Abstract] [Full Text] [Related]

  • 38. The potential of Bruton's tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease.
    Tseng H, Murrell DF.
    Expert Opin Pharmacother; 2024 Aug 13; 25(12):1657-1665. PubMed ID: 39158385
    [Abstract] [Full Text] [Related]

  • 39. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
    Das D, Wang J, Hong J.
    Curr Top Med Chem; 2022 Aug 13; 22(20):1674-1691. PubMed ID: 35927919
    [Abstract] [Full Text] [Related]

  • 40. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
    Ran F, Liu Y, Wang C, Xu Z, Zhang Y, Liu Y, Zhao G, Ling Y.
    Eur J Med Chem; 2022 Feb 05; 229():114009. PubMed ID: 34839996
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.